Fri, July 8, 2022

Matthew Biegler Initiated (BPMC) at Buy and Held Target at $80 on, Jul 8th, 2022

Matthew Biegler of Oppenheimer, Initiated "Blueprint Medicines Corporation" (BPMC) at Buy and Held Target at $80 on, Jul 8th, 2022.

Matthew has made no other calls on BPMC in the last 4 months.



There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $56 on, Friday, July 1st, 2022
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $65 on, Tuesday, June 14th, 2022
  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022


These are the ratings of the 3 analyists that currently disagree with Matthew


  • Derek Archila of "Wells Fargo" Initiated at Sell and Held Target at $40 on, Monday, June 27th, 2022
  • David Lebowitz of "Citigroup" Downgraded from Hold to Strong Sell and Decreased Target to $41 on, Friday, June 10th, 2022
  • Eun Yang of "Jefferies" Upgraded from Hold to Strong Buy and Decreased Target to $78 on, Wednesday, June 1st, 2022